ライフサイエンスコーパス: vascular graft

1 ce finishing impact of a novel silicon-lined vascular graft.

2 ght carotid artery of mice, which acted as a vascular graft.

3 ice after transplantation of the vessel as a vascular graft.

4 biological and autologous tissue-engineered vascular graft.

5 need for a readily available, small-diameter vascular graft.

6 r 5 months, had no thrombus in the device or vascular graft.

7 ery to tissue regeneration and the design of vascular grafts.

8 devices, such as prosthetic heart valves or vascular grafts.

9 roving anti-neointimal activity of synthetic vascular grafts.

10 lusion and neointimal formation of synthetic vascular grafts.

11 cus aureus causes very serious infections of vascular grafts.

12 searched for cancer patients with prosthetic vascular grafts.

13 inhomogeneous uptake was seen more in Dacron vascular grafts.

14 s of synthetic hemodialysis grafts and other vascular grafts.

15 from thrombi forming within collagen-coated vascular grafts.

16 llagen fibrils to guide cell organization in vascular grafts.

17 ce for the construction of tissue-engineered vascular grafts.

18 y and reduces the rejection rate of lung and vascular grafts.

19 and the next generation of tissue-engineered vascular grafts.

20 iovenous fistulae, particularly in synthetic vascular grafts.

21 ition and fibrin accumulation on segments of vascular graft and endarterectomized aorta in vivo.

22 Variability arises as to whether to use a vascular graft and where on the portal system to attach

23 ) pose a detrimental complication when using vascular grafts and are challenging to diagnose and trea

24 nclude rapid endothelialization of synthetic vascular grafts and dialysis fistulas.

25 engineered blood vessels (TEBV) can serve as vascular grafts and may also play an important role in t

26 manufacture arterial-scale tissue engineered vascular grafts and microvascular networks have been wel

27 e of calcification between tissue-engineered vascular grafts and polytetrafluoroethylene grafts.

28 t from numerous investigations, drug-eluting vascular grafts and stents have not solved the main prob

29 cer therapy, wound healing, and drug-eluting vascular grafts and stents.

30 ellent patency of small-diameter nanofibrous vascular grafts, and the unique antithrombogenic propert

31 Design strategies for small diameter vascular grafts are converging toward native-inspired ti

32 te into endothelium, and implanted synthetic vascular grafts are seeded by host SMCs and endothelium.

33 Vascular grafts are used to reconstruct congenital cardi

34 ion of the autograft root within a synthetic vascular graft, are known, the Ross procedure should not

35 , mechanical circulatory assist devices, and vascular grafts, are associated with significant morbidi

36 Here, we used tissue-engineered vascular grafts as a model to demonstrate the potential

37 g the development of infection in artificial vascular grafts (AVGs) used for reconstruction of middle

38 s (ECs) lining surgically implanted arterial vascular grafts (AVGs).

39 et and 125I-fibrin deposition on segments of vascular graft but detectably decreased 111In-platelet a

40 , macrophages, and infiltrating cells in the vascular grafts, but were independent of hemodynamics an

41 uripotent stem cells (hiPSCs), bioengineered vascular grafts (BVGs), and gene editing.

42 nique was employed to construct a functional vascular graft by immobilization of galactosidase on the

43 We fabricated small-diameter vascular grafts by electrospinning fibrin tubes and poly

44 ition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte a

45 Synthetic vascular grafts cannot be used in small vessels because

46 l treatments for vascular disease, including vascular grafts, carotid surgery, and arteriovenous dial

47 were seeded onto collagen-coated segments of vascular graft (collagen segments) and exposed overnight

48 We developed a tissue-engineered vascular graft composed of biodegradable scaffold seeded

49 fibrin deposition for segments of prosthetic vascular graft, deployed endovascular metallic stents, a

50 These insights will help advance vascular graft design.

51 ate superior durability in tissue-engineered vascular grafts, displaying reduced late-term calcificat

52 ynthetic, or more recently tissue-engineered vascular grafts each carry limitations spanning compatib

53 Application of a tissue-engineered vascular graft for small-diameter vascular reconstructio

54 applications in improving tissue-engineered vascular grafts for cardiovascular therapies with small

55 sceptibility and in developing bioengineered vascular grafts for regenerative medicine.

56 roach may be useful to develop new cell-free vascular grafts for treatment of vascular diseases.

57 tails extending downstream from segments of vascular graft from 1.38+/-0.41 x 10(9) platelets in con

58 Here we present an 'off-the-shelf' vascular graft grown from donor fibroblasts in a fibrin

59 oiliac aneurysms with traditional prosthetic vascular grafts has been shown to be effective.

60 he heart through a native artery or a patent vascular graft have a markedly reduced risk of periopera

61 Tissue engineered vascular grafts hold promise for the creation of functio

62 teriosclerosis, renal failure, diabetes, and vascular graft implants.

63 .min-1 immediately upstream from a polyester vascular graft in the unheparinized baboon circulatory s

64 rate derivative are employed as coatings for vascular grafts in sheep.

65 chment and retention of endothelial cells on vascular grafts in vivo, which opens new avenues of rese

66 Vascular graft infection (VGI) is one of the most seriou

67 Participants of the prospective Vascular Graft Infection Cohort (VASGRA) with surgery be

68 years with prosthetic valve endocarditis or vascular graft infection due to M. chimaera, which becam

69 red in 12 patients with endocarditis, 2 with vascular graft infection, and 2 with complicated bactere

70 T is of value in the diagnosis of prosthetic vascular graft infection, but potential pitfalls related

71 therapy control in patients with prosthetic vascular graft infections (PVGIs).

72 Vascular graft infections (VGIs) are serious complicatio

73 of this study was to set up a mouse model of vascular graft infections that closely mimics the human

74 by innate immune cell subsets also promotes vascular graft injury.

75 reduced fibrin formation in collagen-coated vascular grafts inserted into arteriovenous shunts in ba

76 metallic stents or thrombogenic segments of vascular graft interposed in exteriorized long-term arte

77 Essential to tissue-engineered vascular grafts is the formation of a functional endothe

78 Traditional vascular grafts made of synthetic polymers, animal and c

79 aft compliance reveal that tissue-engineered vascular grafts maintain greater compliance (p < 0.0001)

80 strategy to improve re-endothelialization of vascular grafts, maintaining or enhancing mechanical pro

81 as developed to produce arbitrary lengths of vascular graft material from smooth muscle and endotheli

82 Vascular graft or endograft infections (VGEI) pose a det

83 thrombus on metallic stents and segments of vascular graft (P<.001 in all cases for 8-mg/kg doses).

84 By using aortopulmonary vascular graft placement in the fetal lamb (shunt lambs)

85 Using a vascular-graft rat model, we show that RIP, applied loca

86 mplantation of VEGF-functionalized cell-free vascular grafts: regenerative and immunological response

87 d the effects of PPARgamma agonists on human vascular graft rejection using a model in which human ar

88 onses and may be useful for the treatment of vascular graft rejection.

89 demonstrate the promise of tissue engineered vascular grafts, remaining compliant and distensible whi

90 The process of vascular graft remodeling is also involved in endothelia

91 went in utero placement of an aortopulmonary vascular graft (shunt) and were studied 8 weeks after sp

92 ivity when coated on a normally thrombogenic vascular graft situated in an arteriovenous shunt in a b

93 ity to vascular scaffolds, optimize internal vascular graft surface and even help to direct the diffe

94 endothelial cells and thereby confer longer vascular-graft survival.

95 elopment of small diameter tissue engineered vascular grafts (TEVGs) for treating coronary heart dise

96 he first clinical trial of tissue-engineered vascular grafts (TEVGs) identified stenosis as the prima

97 ninvasive MR monitoring of tissue-engineered vascular grafts (TEVGs) in vivo using cells labeled with

98 lls seeded onto functional tissue-engineered vascular grafts (TEVGs) through serial imaging.

99 ls (BMCs) are the earliest tissue-engineered vascular grafts (TEVGs) to be used clinically.

100 rial evaluating the use of tissue-engineered vascular grafts (TEVGs) was stenosis.

101 of neovessel formation in tissue-engineered vascular grafts (TEVGs), but also contribute to graft st

102 e for producing autologous tissue-engineered vascular grafts (TEVGs), which currently suffer from low

103 lls (hiPSCs) for producing tissue-engineered vascular grafts (TEVGs).

104 the long-term efficacy of tissue-engineered vascular grafts (TEVGs).

105 Thus, we create an enzyme-functionalized vascular graft that can catalyze prodrug to release NO l

106 ial progenitor cells to provide a biological vascular graft that resists both clotting and intimal hy

107 es for the construction of tissue-engineered vascular grafts that are nonthrombogenic and have long-t

108 of relaparotomy were hemorrhage (59.3%) and vascular graft thrombosis (22.2%).

109 Vascular graft thrombosis and bleeding are two major iss

110 he secondary endpoints were the incidence of vascular graft thrombosis, postoperative sepsis, patient

111 %) experienced a symptomatic or asymptomatic vascular graft thrombosis.

112 iscussed include endothelial cell seeding of vascular grafts, tissue-engineered vascular conduits, ge

113 tissues, including multilayered skin, bone, vascular grafts, tracheal splints, heart tissue and cart

114 ectly to the endothelialization of acellular vascular grafts under the right chemical and biomechanic

115 ich potentially could lead to drug-entrapped vascular grafts: urokinase-type plasminogen activator wa

116 homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral

117 homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral

118 No vascular grafts (VG) were required for portal vein (PV)

119 Completely autologous tissue-engineered vascular grafts were grown in culture supplemented with

120 The functional vascular grafts were implanted into the rat abdominal ao

121 tissue engineered autologous small-diameter vascular graft, which can function in arterial high pres

122 s components of the mechanical properties of vascular grafts, which is positively correlated with the

123 gnetic forces can be used to rapidly cover a vascular graft with paramagnetically labeled cells.

124 and application of a durable small-diameter vascular graft with tailored regenerative capacity.

125 The development of a living, autologous vascular graft with the ability to grow holds great prom

126 Seeding of small-diameter vascular grafts with endothelial cells (ECs) genetically

127 The ideal engineered vascular graft would utilize human-derived materials to